UNSPSC 51453106: Oxantel embonate

This classification denotes an antihelminthic agent with the molecular formula C23H16O6.C13H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UPY1D732T0, chemically known as 4,4-methylenebis(3-hydroxy-2-naphthoic) acid, compound with (e)-3-(2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl)phenol (1:1) but more generally known as oxantel embonate, which bears US NIH Compound Identifier 5281086. Most nations, for tariff and trade purposes, schedule oxantel embonate under HS 29335995 and SITC 51576.

SMILES: CN1CCCN=C1/C=C/C2CCCC(C2)O.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51453106 Oxantel embonate is a Commodity code for a specific antihelmintic pharmaceutical product, but state and local governments show little recent procurement activity under this code designation. The two most recent records in the opportunity dataset reveal a significant mismatch: the Illinois Department of Public Health's awarded contract targets Doxycycline Hyclate and Ciprofloxacin Hydrochloride (antibiotics unrelated to oxantel embonate), and Seminole County, Florida's solicitation targets Naloxone and drug deactivation systems for harm-reduction and public health purposes. Neither opportunity aligns with the narrow scope of oxantel embonate, a niche antihelmintic medication. When state and local procurement does occur under this code, it appears to move through piggyback cooperative purchasing vehicles—the Illinois contract was awarded through MMCAP Infuse to Chartwell Rx LLC on an Invitation for Bid basis—suggesting that relevant opportunities may cluster within existing statewide or multi-state pharmaceutical cooperative agreements rather than standalone competitive solicitations.

Geographic activity under this code remains sparse and does not support a clear pattern of concentrated demand. The Illinois award and the Seminole County procurement represent isolated instances across two states with no evident repeat buyers or regular procurement cycles visible in the recent record. The Illinois contract, valued at $2,999,999.11 over its full term with renewal options, was completed in August 2026 and represents a piggyback transaction rather than an open competitive opportunity. The Seminole County solicitation (posted June 30, 2026, due July 26, 2023—a date inconsistency in the source record) sought annual volumes of 1,900 units of Naloxone and 800 deactivation systems with quarterly deliveries. Business development professionals should treat this code as a watch category pending clarification of actual oxantel embonate procurement demand; the current record offers no actionable recent opportunities aligned with the code's nominal pharmaceutical scope.